SAME National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
ntroduction	OMB# 0000-0000-0 Exp. Date: 00/00/000
The National Cancer Institute (NCI) and the [COOF NCI clinical trial for [TRIAL DESCRIPTION].	P GROUP NAME] would like your opinions about a new
They have developed a brief online survey tool to research staff in the field to learn any potential issue	quickly and easily solicit feedback from physicians and es with opening and accruing to this trial.
The PDF attachment to your email invitation provid After reviewing this brief document we ask that you	des an overview of the [TRIAL NAME] trial's concept. a take 5 minutes to answer this short survey.
	concerns about the [TRIAL NAME] trial identified from
this survey. We thank you for your assistance!	
To continue and begin the survey, click the "Ne	xt" button below.
	xt" button below.
To continue and begin the survey, click the "Ne	
To continue and begin the survey, click the "Ne If you experience any technical difficu at User-Centered Design at	
To continue and begin the survey, click the "Ne	Next>

You may skip any questions that you prefer not to answer. You are also free to stop participating at any point during the survey and have your responses deleted by clicking the "Opt out of survey" box at the top of each survey page.

This brief survey should only require approximately 5 minutes of your time.

Please click the "Next" button if you consent to taking this survey.

Next -->

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 208927974, ATTN: PRA (0000-0000-00). Do not return the completed form to this address.

> If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at <u>survey@user-centereddesign.com</u>



	National Cancer Institute	U.S. National Institutes of Healt	h www.cancer.gov
			Opt out of survey
Plance	reply to all questions from the perspective of your s	ito	
		ite.	
1. Plea	ase indicate which best describes your site:		
0	My practice is located within an academic medical c	enter	
0	My practice is located within an NCI-Designated Ca	ncer Center	
۲	My practice is located within a community hospital (i hospitals)	.e., non-academic, medic	al center
0	I/We are a free-standing private practice		
0	Other:		
1a.	What best describes the size of your community hos	pital compared to others?	,
	We are a small-size community hospital (fewer the second secon	an 100 beds)	
	We are a mid-size community hospital (between "	100-250 beds)	
	We are a large-size community hospital (more that	an 250 beds)	
2. Plea	ase indicate which best describes your site's affiliation	on(s): (Please check all th	at apply)
	CCOP		
	MB-CCOP		
	NCCCP		
	ALLIANCE		
	ECOG-ACRIN		
	SWOG		
	NRG		
	COG		
	EORTC		
	COGNO (Cancer Australia)		
	NCIC		
	Other:		
3. Whi	ch category best describes your role at your practice	?	
	Physician		
	Staff member/other		
0			
< Bac	k	Sa	we and Continue>
	If you experience any technical difficulties, please co at User-Centered Design at <u>survey@user-</u>		

Attachment_7_prospectivesurvey

Note: Q1a appears only if "My practice is located within a community hospital" is selected for Q1.

If user selects "physician" to Q3, continue below. If user selects "Staff member/other", continue <u>HERE</u>.

	ancer Institu	ite	U.	S. National Institutes of Health	www.cancer.g
				1	Opt out of sur
What type of onco	logy best des	cribes your expe	ertise?		
Medical oncol	ogy				
 Surgical oncol 					
Radiation once					
Gynecologic o					
O Pediatric onco	ology				
[VARIABLE]					
Other:]	
The [TRIAL NAME entifically interesti RQ1: [INSERT R 5a. How scientific	ing it is to you	I. RIAL SUMMARY	SHEET]	l. [For each,] Please to	ell us how
Not at all				Very	
interesting				interesting	
0	0	0	0	0	
Please elaborate:					
RQ2: [INSERT R				you?	
5b. How scientific Not at all interesting				Very interesting	
	0	0	0		
Not at all	0	0	0		

	ancer Institu	ıte	Ú.	S. National Institutes of H	ealth www.cancer.gov
					Opt out of surve
Assuming the [TR ndings will have or				hat impact do you	believe the
Low impact				High impact	
\odot	\bigcirc	\odot	\odot	\odot	
The potential be	nefits of this	trial for patient		e effort and reso	ources required
The potential be to open and con Strongly	nefits of this	trial for patient		Strongly	ources required
to open and con	nefits of this	trial for patient			ources required
The potential be to open and con Strongly	nefits of this	trial for patient		Strongly	ources required
The potential be to open and con Strongly Disagree	enefits of this aduct it at my	trial for patient site.	is are worth th	Strongly	Save and Continue -

	lational Ca	ncer Institut	e		U.S. National Institutes of H	lealth www.cancer.gov
						Opt out of survey
	what you rea ial at your si		summary shee	t, how interes	sted are you in oper	ning the [TRIAL
	t at all rested				Very interested	
	0	۲	\odot	\odot	0	
	hat are the to t up to 3.]	op reasons wh	iy you are not	that intereste	d in opening the [Ti	RIAL NAME] trial?
 To Lir To high m Fir Co Do Do To needed 	o many com nited interes o difficult to efusals) nancial cost oncerns about the not match ot scientifical o difficult to	peting trials for t by oncologis accrue patient to our site wor ut drug availab h our patient p ly interesting	t(s) here ts (e.g., randor uld be too grea bility population enough	mization, scre at (e.g., non-r	eening many to ider eimbursable expens coordination require	ses)
< Back						Save and Continue>
	lf yc		technical difficultion tered Design at su		ct the survey administrato ereddesign.com	r

Note: This 8a appears if the user selects either of the two leftmost radio buttons for Q8.

National C	Cancer Institut	е	U.S.	National Institutes of He	alth www.cancer.gov
					Opt out of survey
8. Given what you n NAME] trial at your		summary sheet	, how interested	are you in openi	ing the [TRIAL
Not at all interested				Very interested	
\odot	\odot	•	\odot	0	
8a. What are the [Select up to 3.]	top reasons wh	ny you might be	interested in o	pening the [TRIA	L NAME] trial?
 High level of Fills unmet n Limited burde 	ing trials for this f interest by onco need for our curro en on patient (e. y interesting rese	ologist(s) in the ent patient pop .g., logistics, co	ulation ost)		
Ease in accr	uing to the trial			rdination, have e	quipment
Limited non-	reimbursable ex of study drug(s)	cpenses			
< Back					Save and Continue>
			s, please contact the rvey@user-centered	e survey administrator Idesign.com	

Note: This Q8a appears if the user selects any of the three rightmost radio buttons for Q9.

部派 National C	ancer Institu	ite		U.S. National In	stitutes of Health	www.cancer.gov
					C	pt out of survey
For each of the tri ifficult to <u>open or ru</u>				l us whether	r or not it will n	nake it
How difficult w	ill this require un this trial at		o open or	Not make it difficult to open/ run the trial	Make it somewhat difficult to open/ run the trial	Make it <u>very</u> difficult to open/run the trial
[INSERT ITEM 2	FROM TRIA	L SUMMARY S	HEET]	0	0	0
[INSERT ITEM N	FROM TRIA	L SUMMARY S	SHEET]	0 0 0		0
[INSERT ITEM 1	FROM TRIA	L SUMMARY S	HEET]			
[INSERT ITEM 3	FROM TRIA	L SUMMARY S	HEET]			
[INSERT ITEM 4	FROM TRIA	L SUMMARY S	HEET]	0	0	0
0. Overall, how diff Not at all difficult	îcult do you be	elieve the [TRIA	L NAME] tri	al will be to Very d		site?
0	0	0	0	0		
Back						and Continue>
If		y technical difficultie intered Design at su				

部進 National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
	Opt out of surve
1. How often do you see a patient who may be eligit [YPE])?	ble for the [TRIAL NAME] trial (i.e., [PATIENT
=select= ‡	
2. Which specialty at your institution would most like ial to a potentially eligible patient?	ely be in the position to recommend or refer thi
Medical oncology	
 Surgical oncology 	
Radiation oncology	
Gynecologic oncology	
Pediatric oncology	
O [VARIABLE]	
Other (please specify):	
3. If your site were to open the [TRIAL NAME] trial, a ite could accrue to the trial in a year?	about how many patients do you believe your
(Number of patients - integers only)	
< Back	Save and Continue

How difficult will this issue make it to accrue patients to this trial?	make it difficult to accrue patients to the trial	Make it somewhat difficult to accrue patients to the trial	Make it very difficult to accrue patients to the trial
Burden on patient to participate in the trial (e.g., logistics, time)	0	Θ	0
Cost to the patient (e.g., insurance, reimbursement)	0	0	0
Patients declining to enroll (e.g., unwilling to randomize, prefer one study arm)	0	0	0
Explaining the trial's details to a patient, including consenting	0	0	0
Getting patients referred to the trial	0	0	0
Inclusion/exclusion criteria of the trial	0	0	0

	National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
		Opt out of survey
	w many similar trials are open at your site that wo ation as the [TRIAL NAME] trial? (Integers only)	uld compete for the same patient
	Number of similar trials open at you	ur site from each sponsor
	# competing trials that are sponsored by NCI (in	cluding cooperative group trials)
	# competing trials that are sponsored by pharma	aceutical/biotech industry
	# competing trials that are investigator initiated t	trials from academic medical centers
[TRIAI	-SPECIFIC QUESTION 1 HERE]	
[TRIAI	-SPECIFIC QUESTION 2 HERE]	
< Bac	ĸ	Save and Continue>
	If you experience any technical difficulties, please at User-Centered Design at <u>survey@us</u>	

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
	Opt out of survey
16. Do you have any final comments about the [TRIA	NAME] trial that you would like to share?
< Back	Submit Survey>
If you experience any technical difficulties, plea at User-Centered Design at <u>survey@</u>	

urvey Complete	Opt out of surv
	pleting this survey!
Your answers have been	submitted anonymously.
	back regarding the trial. Ian in advance for any concerns identified.
	ter the survey closes, please send an email to @mail.nih.gov
You may now cl	ose this window.
	s, please contact the survey administrator vev@user-centereddesign.com

END OF SURVEY

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
i long (Bu	Opt out of survey
Please reply to all questions from the perspective of ye	our site.
1. Please indicate which best describes your site:	
 My practice is located within an academic medi My practice is located within an NCI-Designate My practice is located within a community hosp hospitals) 	d Cancer Center
 I/We are a free-standing private practice 	
Other:	
1a. What best describes the size of your community	
We are a mid-size community hospital (betw	
O We are a large-size community hospital (more	
 MB-CCOP NCCCP ALLIANCE ECOG-ACRIN SWOG NRG COG EORTC COGNO (Cancer Australia) NCIC Other: 	
 3. Which category best describes your role at your pra Physician Staff member/other 	Save and Continue>

Attachment_7_prospectivesurvey

Note: Q1a appears only if "My practice is located within a community hospital" is selected for Q1.

新航 National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
	Opt out of surve
51. What category best describes your role within	n your practice? (Select one)
Research Nurse	
 Site Administrator / Manager 	
 Coordinator 	
 CRA (non-nurse) 	
 Regulatory Specialist 	
 Data Manager 	
Other:	
< Back	Save and Continue

	National	Cancer Institut	e	U.	S. National Institutes of Hea	Ith www.cancer.gov
						Opt out of survey
		u read in the <u>tria</u> in opening the []			sted do you believe	the oncologists
	Not at all nterested				Very interested	
	0	•	\odot	\odot	0	
		he top reasons v elect up to 3.]	vhy your site r	night not be inte	erested in opening t	he [TRIAL
hig nee	Does not ma Too difficult h refusals) Financial co Concerns al Too difficult eded) Too many co Limited inter	est to our site wou bout drug availab	opulation ts (e.g., rando uld be too grea bility udy (e.g., burd or this cancer t(s) here	at (e.g., non-rein den on staff, con	ning many to identif mbursable expense ordination required,	s)
The to e	e potential b	you agree or dis penefits of this t onduct it at our s	rial for patien		ne effort and resou Strongly Agree	rces required
	O	0	0	0	G	
Please		on your response	above:	-	5	ave and Continue>
				es, please contact t urvey@user-center	he survey administrator addesign.com	

Attachment_7_prospectivesurvey

Note: This QS2 appears if the user selects either of the two leftmost radio buttons for QS2.

National (Cancer Institu	te	U.	S. National Institutes of Health	www.cancer.gov
				1	Opt out of survey
S2. Given what yo at your site will be				sted do you believe th	e oncologists
Not at all interested				Very interested	
\odot	\odot	•	\odot	\odot	
S2a. What are t trial? [Select up		why your site m	ight be interes	ted in opening the [Tf	RIAL NAME]
Limited non-	-reimbursable e	xpenses			
Limited burd	len on patient (e	a.g., logistics, co	st)		
Fills unmet r	need for our cur	rent patient pop	ulation		
Few competition	ting trials for this	cancer			
Ease in acc	ruing to the trial				
Ease of doir	ng the study (e.g	., limited burder	n on staff or co	ordination, have equi	pment
needed)					
		ologist(s) in the	practice		
	of study drug(s)				
	y interesting res	earch question(s)		
Other:				ļ	
S3. How much do	you agree or di	sagree with this	statement?		
The potential b to open and co			s are worth th	ne effort and resourc	ces required
Strongly				Strongly	
Disagree				Agree	
\odot	\odot	0	\odot	\odot	
Please elaborate o	on your respons	e above:			
< Back				Sav	e and Continue>
		y technical difficultien Intered Design at sur		he survey administrator addesign.com	

Note: This QS2 appears if the user selects any of the three rightmost radio buttons for QS2.

	vill this require run this trial at	ement make it to open or your site?	Not make it difficult to open/ run the trial	Make it <u>somewhat</u> <u>difficult</u> to open/ run the trial	Make it <u>very</u> difficult to open/run the trial
[INSERT ITEM	2 FROM TRIA	L SUMMARY SHEET]	0	0	0
[INSERT ITEM	N FROM TRIA	L SUMMARY SHEET]	0	0	0
-		L SUMMARY SHEET]	0	0	0
-		L SUMMARY SHEET]	0	0	0
INSERT ITEM	3 FROM TRIA	L SUMMARY SHEET]	0	0	0
-		elieve the [TRIAL NAME]	trial will be to Very d		site?
i. Overall, how di Not at all		elieve the [TRIAL NAME]			site?

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
	Opt out of survey
S6. How often does your practice see a patient wh [PATIENT TYPE])?	o may be eligible for the [TRIAL NAME] trial (i.e.,
-select- :	
S7. Which specialty at your institution would most this trial to a potentially eligible patient?	likely be in the position to recommend or refer
Medical oncology	
 Surgical oncology 	
Radiation oncology	
Gynecologic oncology	
Pediatric oncology	
(VARIABLE)	
Other (please specify):	
S8. If your site were to open the [TRIAL NAME] tria site could accrue to the trial in a year?	al, about how many patients do you believe your
(Number of patients - integers only)	
< Back	Save and Continue>
If you experience any technical difficulties at User-Centered Design at sun	

How difficult will this issue make it to accrue patients to this trial? make it officult difficult difficult to accrue patients somewhat difficult difficult to accrue patients very difficult to accrue patients	0	Θ	0 0			
Not make it patients to the [TRIAL NAME] trial. Not make it difficult to accrue patients to the trial? Make it somewhat difficult to accrue patients to the trial Make it somewhat difficult to accrue patients to the trial Make it somewhat difficult to accrue patients to the trial Make it somewhat difficult to accrue patients to the trial Make it somewhat difficult to accrue patients Cost to the patient (e.g., insurance, reimbursement) O O O Explaining the trial's details to a patient, including consenting O O O			0	0)	
Cost to the patient (e.g., insurance, reimbursement) Image: Cost to the patient (e.g., insurance, reimbursement) Explaining the trial's details to a patient, including consenting Image: Cost to the patient (e.g., insurance, reimbursement)	rue patients to t	ult will this issue	E] trial. e make it to accrue	Not make it difficult to accrue patients	Make it <u>somewhat</u> <u>difficult</u> to accrue patients	difficult to Make it very difficult to accrue patients t the trial
Explaining the trial's details to a patient, including	Getting patients	referred to the tr	ial	0	0	0
consenting	Cost to the patie	ent (e.g., insuran	ce, reimbursement)	0	0	0
Inclusion/exclusion criteria of the trial		rial's details to a	patient, including	0	0	0
	Inclusion/exclus	sion criteria of the	e trial	0	0	0
Burden on patient to participate in the trial (e.g., logistics, o o		ent to participate	in the trial (e.g., logistic	s, 🔘	0	0
Patients declining to enroll (e.g., unwilling to randomize, prefer one study arm)			, unwilling to randomize), O	0	0

	National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
		Opt out of survey
	How many similar trials are open at your site that ation as the [TRIAL NAME] trial? (Integers only)	would compete for the same patient
	Number of similar trials open at ye	our site from each sponsor
	# competing trials that are sponsored by NCI (i	ncluding cooperative group trials)
	# competing trials that are sponsored by pharm	aceutical/biotech industry
	# competing trials that are investigator initiated	trials from academic medical centers
[TRIA	L-SPECIFIC QUESTION 1 HERE]	
[TRIA	L-SPECIFIC QUESTION 2 HERE]	
< Bac	sk	Save and Continue>
	If you experience any technical difficulties, plea at User-Centered Design at <u>survey@</u>	

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
	Opt out of survey
S12. Do you have any final comments about the [TRL	AL NAME] trial that you would like to share?
< Back	Submit Survey>
If you experience any technical difficulties, plea at User-Centered Design at <u>survey@</u>	

urvey Complete	Opt out of surve
Thank you for con	pleting this survey!
Your answers have been	n submitted anonymously.
	dback regarding the trial. Ian in advance for any concerns identified.
	fter the survey closes, please send an email to @mail.nih.gov
You may now c	lose this window.